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AbstrACt
Introduction Randomised clinical trials to date 
investigating the efficacy of bisphosphonates in knee 
osteoarthritis (OA) have found divergent results, 
with a recent meta-analysis finding no superiority of 
these drugs over placebo. Whether particular patient 
subgroups are more likely to benefit from this therapy 
than others is still unclear. We aim to investigate 
the effects of bisphosphonates compared with a 
control group (placebo, no treatment, another active 
treatment) on clinical and structural outcomes in 
specific knee OA subpopulations with possible distinct 
rates of subchondral bone turnover.
Methods and analysis Medline, Embase, 
Scopus, Web of Sciences and Cochrane Central 
Register of Controlled Trials will be searched from 
inception to February 2018. Randomised clinical 
trials will be eligible if they reported at least one 
potential treatment effect modifier at baseline: 
gender, menopausal status, age, body mass index, 
radiographic stage, knee pain severity, presence of 
bone marrow lesions, levels of biochemical markers 
of bone turnover (serum and/or urinary) and systemic 
bone mineral density status. Authors of original trials 
will be contacted to obtain individual patient data from 
each study. Risk of bias will be assessed using the 
Cochrane Collaboration’s tool. The primary outcomes 
will include pain and radiographic joint space width 
loss. Studies using other MRI-based assessment of 
disease progression will also be eligible. Outcomes 
will be grouped into short-term (≤3 months), 
intermediate-term (>3 months; ≤12 months) and 
long-term (>12 months). Regression models will be 
used, adding an interaction term for each subgroup of 
interest to determine possible subgroup effects. There 
was no source of funding for this study.
Ethics and dissemination Dissemination of our 
findings is planned to occur through conference 
presentations, publication in peer-reviewed journals 
and social media. No formal ethics approval is 
generally required as no new data collection will be 
undertaken.
PrOsPErO registration number CRD42018093327.
IntrOduCtIOn  
Osteoarthritis (OA) affects more people than 
any other type of arthritis.1 The overall lifetime 
risk of suffering from knee OA is estimated to 
range from 14% to 44% for the general popu-
lation.2 3 However, specific subpopulations 
are at higher risk: around 20% to 60% of 
obese individuals and 34% to 56% of individ-
uals with significant knee injury will develop 
knee OA.2 4 OA was ranked the 12th major 
cause of global disability in 2016 among all 
other medical conditions and showed one of 
strengths and limitations of this study
 ► Particular subgroups of patients with knee osteoar-
thritis (OA) may be more likely to benefit from bis-
phosphonate therapy than others. Previous clinical 
studies, including conventional meta-analyses, were 
unable to address this important issue.
 ► We will use individual patient data meta-analysis, 
which allows for more consistent identification and 
extraction of common individual-level characteris-
tics, standardised outcome measures and greater 
statistical power to conduct subgroup analyses.
 ► The OA Trial Bank is an international initiative aimed 
to foster research on the identification of OA pa-
tient subgroups for targeted treatment. A steering 
committee has assessed and approved this study 
initiative and will provide support for all procedures 
related to data collection, transfer and management.
 ► The analyses planned will depend on availability of 
data provided for this study.
 ► The variables that will be tested as potential treat-
ment effect modifiers are possibly associated with 
but are not direct measures of distinct rates of sub-
chondral bone turnover.
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the greatest rises in years lived with disability over the last 
decade.5 This high and growing burden of OA threatens 
healthcare systems and desperately demands more effi-
cacious treatments to prevent the structural and clinical 
deterioration associated with this condition.
Subchondral bone is a potential target in OA as there 
is extensive literature showing the important role of 
subchondral bone remodelling in OA pathogenesis.6–9 
Microstructural subchondral bone changes start early 
in the OA process, promoting neovascularisation and 
growth of sensory nerves to the deepest cartilage layers, 
which facilitate the exchange of local factors between 
these tissues.6 Preclinical studies have demonstrated that 
bone and cartilage interact through biochemical, cellular 
and mechanical mechanisms, which contribute to joint 
pain, changes in cartilage homoeostasis and subsequent 
joint damage.9 10 The subchondral bone in OA knees 
has been characterised as having a high turnover state, 
resulting in relative hypomineralisation and bone weak-
ness; however, increased subchondral bone thickness 
and volume have also been observed, which might result 
in an overall increase in subchondral bone stiffness.10 A 
preclinical study suggested an increase in bone resorp-
tion in the onset of OA development while increased 
bone formation prevails in later stages.11 Nevertheless, 
early subchondral bone changes in human OA joints are 
still less understood.
Bisphosphonates are a class of medication commonly 
used in the treatment of osteoporosis and other meta-
bolic bone disorders, acting primarily on osteoclasts 
in active remodelling sites in the skeleton.12 Through 
the inhibition of osteoclast-induced bone resorption, 
bisphosphonates decrease bone remodelling and 
improve bone mineralisation and trabecular microar-
chitecture.12 Numerous preclinical studies have shown a 
protective effect of bisphosphonates on joint structure, 
improving subchondral bone quality and protecting 
the hyaline cartilage from damage,13 14 in addition to a 
possible reduction in synovitis.14 15 Moreover, observa-
tional clinical studies have suggested a potential benefit 
of bisphosphonates in reducing knee pain,16joint space 
width loss,16 spinal osteophyte progression17 and rate 
of total knee replacement.18 19 However, a few of these 
studies were specifically conducted in populations with 
osteoporosis and it is unclear whether the subchondral 
bone in these individuals is more prone to beneficially 
react to the effect of bisphosphonates.17 19 20 Despite these 
encouraging results, clinical trials to date testing the 
effectiveness of bisphosphonates on clinical and struc-
tural outcomes have found mixed results.21 Moreover, a 
recent systematic review and meta-analysis on bisphos-
phonates in knee OA including seven randomised, place-
bo-controlled trials (3013 patients) found no differences 
in pain, function and the proportion of patients experi-
encing radiographic progression.22
There is a growing body of literature describing 
heterogeneity in the pathogenesis and clinical and 
structural manifestations of OA.23 It has been suggested 
that increased subchondral bone remodelling may not 
be universal to all patients or through all stages of the 
disease process.24–27 As a consequence, targeting the OA 
population as a whole may conceal beneficial effects of 
bisphosphonates if only specific subgroups of patients 
experience benefits from the therapy. Other authors 
have highlighted the need to identify the ‘right people 
at the right time’ in whom bisphosphonates may be 
of benefit.24 Post-menopausal women with decreased 
subchondral bone density and increased remodelling,25 
early OA stages26 28 and presence of bone marrow lesions 
(BMLs)29 30 were particularly highlighted as potential 
subpopulations likely to benefit from bisphosphonates.27 
In addition, there is a marked difference in potency 
across different types of bisphosphonates. This variation 
is mainly related to the presence of a nitrogen molecule 
in the structure of the most contemporaneous bisphos-
phonate drugs, which could also be a factor affecting the 
magnitude of treatment effect.12
The OA Trial Bank is an initiative aimed to foster 
research on the identification of OA patient subgroups for 
targeted treatment through individual patient data (IPD) 
meta-analysis.31 32 IPD meta-analysis is the gold standard 
for reviews aiming to synthesise the evidence of clinical 
studies and is a useful technique to conduct well-defined 
subgroup analyses as it enables more consistent identifi-
cation and extraction of common individual-level char-
acteristics, standardised outcome measures and greater 
statistical power to conduct subgroup analyses.33 34 Prior 
conventional meta-analyses on bisphosphonates in OA 
were unable to address this important issue of identifying 
subgroups of individuals who may most benefit from 
bisphosphonate therapy.21 22 35 The steering committee 
of the OA Trial Bank ensures the appropriateness of the 
research question and methodology and a strategy is in 
place to contact the authors of eligible clinical trials in 
order to obtain original research data from each study.
The unacceptable lack of disease-modifying agents 
in OA combined with suggestive evidence of a role for 
bisphosphonates in selected patient subgroups underlies 
the need for methodologically sound studies to poten-
tially identify differential effects of bisphosphonates in 
predefined knee OA subpopulations. Under the exper-
tise of the OA Trial Bank, we aim to conduct a systematic 
review with IPD meta-analysis to perform subgroup anal-
ysis of existing clinical trials on the efficacy of bisphos-
phonates on clinical and structural outcomes in patients 
with knee OA.
MEthOds
A summary of the study proposal along with the research 
question has been approved by the steering committee of 
the OA Trial Bank before the preparation of the full study 
protocol. We followed the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses-IPD (PRISMA-IPD) 
checklist to ensure the quality of reporting of this system-
atic review and IPD meta-analysis protocol.36
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Literature search
Identification of studies
We will search the following databases: Medline, Embase, 
Scopus, Web of Sciences and Cochrane Central Register 
of Controlled Trials from inception to February 2018. 
Reference lists of selected studies and relevant reviews 
will be hand searched for additional studies and Google 
Scholar will be searched for additional citations associ-
ated with the final included studies. The search strategy 
will contain a combination of key search terms (and 
related terms) including three main filters: (1) popu-
lation: OA and knee; (2) intervention: bisphosphonate, 
clodronate, tiludronate, etidronate, alendronate, zole-
dronic acid (or zoledronate), pamidronate, risedronate, 
neridronate, ibandronate, olpadronate, incadronate; (3) 
study design: randomised and trial. The full search strategy 
can be found in online supplementary appendix 1. All 
titles and abstracts will be imported into EndNote X7 for 
the screening process.
Screening process
Two independent reviewers (LAD, WMO) will screen all 
titles and abstracts for potentially eligible studies. In a 
second step, the full text of the selected studies will be 
assessed for eligibility by the same independent reviewers 
and any disagreements will be discussed and resolved with 
a third reviewer (DJH) if consensus is not achieved. The 
results of the literature search will be summarised in a 
flowchart as suggested by the PRISMA guidelines.37
study selection
All trials that fulfil the following eligibility criteria will be 
included in the IPD meta-analysis.
Inclusion criteria
Participants
Studies including participants with a diagnosis of symp-
tomatic knee OA according to the American College of 
Rheumatology classification criteria,38 physician diag-
nosis or other diagnostic criteria based on clinical mani-
festations, with or without radiographic data.
Intervention
All bisphosphonates will be considered for the purpose of 
this study regardless of the route of administration (oral, 
intravenous or intra-articular), dosage or molecular char-
acteristics (nitrogenous vs non-nitrogenous).
Control
Trials comparing bisphosphonate treatment with a 
control group (placebo, no treatment or another active 
treatment) will be eligible.
Outcome
Trials will be eligible if there are individual patient data 
available for both bisphosphonate and control groups 
on at least one of the following outcomes: knee pain 
(primary clinical outcome), irrespective of the scale used, 
or structural disease progression based on radiographic 
joint space width (JSW) (primary structural outcome) or 
other MRI-based assessment of disease progression, at 
baseline and any follow-up time points.
Study design
Only studies that are randomised clinical trials will be 
eligible.
Variables for subgroup analyses: All studies included in the 
IPD meta-analysis should have at least one of the variables 
that will be used as potential treatment effect modifiers 
assessed at baseline (described in the 'Subgroup Analyses' 
section below).
Exclusion criteria
Studies in which the intervention group received bisphos-
phonate combined with another active treatment (phar-
macological or non-pharmacological) will be excluded. 
We will also exclude studies exclusively assessing the effect 
of bisphosphonates in animals or in joints other than the 
knee, reviews, editorials, conference abstracts with no 
other source of data available, and non-randomised trials. 
There will be no language restriction.
data acquisition, transfer and checks
We will use the same strategy for data acquisition 
and transfer used in all other studies in the OA Trial 
Bank.31 39 The corresponding author of the eligible trials 
will be contacted first by email with two subsequent email 
reminders, followed by telephone if needed. If the corre-
sponding author is unavailable, the other trial authors 
and/or institutions listed will be contacted. On favour-
able response and willingness to share the data, data 
deliverers will be asked to sign the data delivery license 
agreement, which will contain items on input data, obli-
gations, ownership of data, terms, authorship, subgroup 
analyses planned and dissemination of the results. All 
de-identified data will be transferred to a secure data-
base at Erasmus University Medical Center, Rotterdam, 
the Netherlands. Data sets will be accepted in any format, 
provided that variables and categories are adequately 
labelled within the data set or with a separate codebook. 
To ensure quality, data from all studies will be checked 
for duplicates and completeness. Outliers or unusual 
values will be assessed by range checks. Numbers related 
to participants baseline characteristics and changes over 
time for the primary outcome measures will be compared 
with published papers to check for consistency. In case 
of differences, authors of the original studies will be 
contacted to clarify any discrepancies.
Methodological quality assessment
Two raters (LAD, WEvS) will independently assess the 
risk of bias and the quality of evidence of the included 
studies using the 12 items from the Cochrane Collab-
oration’s tool.40 The following areas will be assessed: 
sequence generation; allocation concealment; blinding 
of participants, personnel and outcome assessment; 
incomplete outcome data; selective reporting and other 
sources of bias. Each item will be scored as yes (low risk 
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of bias), no (high risk of bias) or unclear. A low risk of 
bias study will be defined as fulfilling six or more of the 
criteria items, as previously used in other studies in the 
OA Trial Bank.39 41 Any disagreements will be discussed 
and resolved by consensus or consulting a third reviewer 
(BTS).
subgroup analyses
The characteristics that will be assessed as potential treat-
ment effect modifiers if sufficient data are available are 
(table 1): (1) gender: male vs female; (2) menopausal 
status: premenopausal vs post-menopausal; (3) age (as 
continuous variable); (4) body mass index (BMI): obese 
(BMI ≥30 kg m-2) vs non-obese; (5) radiographic disease 
stage, assessed by baseline radiographic minimum JSW 
or Kellgren Lawrence grade,42 depending on data avail-
ability; (6) knee pain severity at baseline (as continuous 
variable); (7) BMLs: presence of at least one moderate 
or large BML on MRI vs absence or presence of small 
BML; (8) baseline levels of serum or urinary biochem-
ical markers of bone turnover (eg, CTX-I, CTX-II and 
NTX-I): ≥ or < mean value (values will be transformed if 
the distribution is skewed); and (9) systemic bone mineral 
density status (either as continuous variable or presence 
vs absence of osteopenia/osteoporosis).
data analysis and reporting
A descriptive synthesis of each study and participants’ 
demographic characteristics will be conducted. Publica-
tion bias will be investigated using funnel plot analysis.43 
Assessment of heterogeneity across trials for the primary 
outcomes will be based on the I2. A complete case analysis 
will be carried out preferably over imputation of missing 
data. If a high proportion of missing data is encountered, 
multiple imputation will be used for potential treatment 
effect modifiers and covariates within each trial due to 
missing at random assumption before the results are 
pooled44 and a sensitivity analysis will be carried out to 
assess any difference in results compared with the non-im-
puted data set.
For the analysis of the magnitude of treatment effect in 
the whole population, including all studies, and in each 
specific subgroup of interest described above, a one-step 
approach meta-analysis will be carried out as the primary 
analysis.45 This is done by appending the data from all 
studies after appropriate standardisation of variables 
and outcomes has taken place and performing the anal-
yses in this new dataset. To assess for possible subgroup 
effects, interaction effects will be determined using 
random-effects regression models, adding an interaction 
term for each subgroup of interest and adjusting for a 
variable representing the study to account for residual 
confounding by study differences. As a secondary anal-
ysis, a two-stage meta-analysis approach will be used. 
According to this approach, subgroup analysis will be 
performed within each trial for all standardised outcomes. 
In a second step, interaction terms will be pooled for 
each potential predictor using random-effects models in 
the same way as conventional meta-analysis with aggre-
gated data. The main comparison will be made between 
bisphosphonate and placebo and other comparisons will 
be planned according to the availability of trials and data.
Risk ratios and 95% CI will be the preferred measure of 
effect to be presented for dichotomous outcomes (radio-
graphic progression, other MRI-based assessment of 
disease progression and progression to total knee replace-
ment). Mean differences and 95% CI will be presented 
for continuous outcomes (knee pain and physical func-
tion) if the same scale was used for outcome assessment 
across trials or standardised mean differences and 95% CI 
if different scales were used. Primary outcomes (pain and 
radiographic JSW) will be grouped into three main time-
points of assessment: short term (≤3 months), interme-
diate term (>3 months;≤12 months) and long term (>12 
months). Radiographic assessment of progression based 
on JSW will be dichotomised into progression if JSW loss 
≥ 0.7 mm or non-progression if JSW loss <0.7 mm if JSW 
measurements are available, which is the smallest detect-
able difference of this method.46 Secondary outcomes 
will include physical function, progression to total knee 
replacement and structural progression based on other 
OA-related features on MRI and radiograph such as 
Kellgren Lawrence grade (KLG)42 and size or volume 
of BMLs, if available. The incidence of adverse events 
and serious adverse events will be compared between 
the intervention and control groups using IPD from all 
studies. We will use intention-to-treat analysis preferably 
over per-protocol or as-treated analysis. The results will 
be interpreted taking into account the number of trials 
Table 1 Potential treatment effect modifiers
Characteristic Description
Gender Male vs female
Menopausal status Premenopausal vs 
postmenopausal
Age (years) Continuous variable
Body mass index* (BMI) BMI ≥30 (obese) vs <30 
(non-obese)
Radiographic osteoarthritis 
(OA) stage
Radiographic minimum joint 
space width (continuous); 
Kellgren Lawrence grade
Baseline knee pain severity Continuous variable
Bone marrow lesion (BML) Presence of at least one 
moderate to large BML vs 
absence of presence of 
small BML
Baseline levels of systemic 
markers of bone turnover (eg, 
CTX-I, CTX-II and NTX-I)
≥ mean value vs < 
mean value†
Systemic bone density status Either as continuous variable 
or presence vs absence of 
osteopenia/osteoporosis
*Measured in kg m-2.
†Values will be standardised if the distribution is skewed.
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and participants included in the analyses and the meth-
odological quality of the trials.
To determine the influence of bisphosphonate type 
on pooled treatment effects, analyses for the primary 
outcomes will be stratified by route of administration (ie, 
intravenous vs oral vs. intra-articular) and molecular char-
acteristics (nitrogeneous vs non-nitrogenous) using data 
from all trials included in the meta-analysis.
Patient and public involvement
There are two members of the Arthritis Research UK OA 
Research Users Group who are representatives of patient 
and public involvement in the Steering Committee of the 
OA Trial Bank. The Steering Committee assesses all study 
proposals before the preparation of the protocol and 
approves and agrees on the study's design and methods, 
subgroups proposed and statistical analysis.
EthICs And dIssEMInAtIOn
No formal ethics approval is generally required as no new 
data collection will be undertaken. If ethics approval is 
required in order to perform new analyses in any indi-
vidual eligible study, approval will be requested and 
obtained before conducting any additional analysis. A 
data delivery license agreement will be provided and 
signed by one of the authors of each of the original trials 
providing data for this study. Dissemination of our find-
ings is planned to occur through presentations at interna-
tional conferences, publication in peer-reviewed journals 
and social media such as Twitter.
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